MedTrace Logo

Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma

NCT06712459 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-01-16

No results posted yet for this study

Summary

Histological transformation in Splenic Marginal Zone Lymphoma (t-SMZL) represents an unmet clinical and biological need, invariably associated with poor prognosis and reduced overall survival. At the present time, there are no recommended treatments intended specifically to t-SMZL and little is known about t-SMZL genetic complexity. The aim of this study is to provide information that will help clinicians to better understand the complexity of the disease. The information gained from this study will also lead to more specific and effective treatment for patients with t-SMZL.

Conditions

  • Transformed Splenic Marginal Zone Lymphoma

Sponsors & Collaborators

  • International Extranodal Lymphoma Study Group (IELSG)

    lead OTHER

Principal Investigators

  • Luca Arcaini, MD · Fondazione IRCCS Policlinico San Matteo

  • Davide Rossi, MD · Oncology Institute of Southern Switzerland (IOSI) and Institute of Oncology Research (IOR)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-13
Primary Completion
2029-03-31
Completion
2029-03-31

Countries

  • United States
  • Belgium
  • France
  • Italy
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06712459 on ClinicalTrials.gov